Cantor Fitzgerald analyst Ross Osborn initiated coverage of Prenetics with an Overweight rating and $7 price target. Osborn holds a favorable view of the consumer and clinical testing markets the company addresses and believes Prenetics’ commercialization strategy is unique and sound, the analyst tells investors in a research note. Additionally, Osborn believes the company’s shares are attractively valued.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PRE:
- Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
- PRE Blasts Up on FDA Approval
- Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
- Prenetics: ACT Genomics receives FDA clearance for ACTOnco
- Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology